[Opinion] # Krystal Biotech Advances VYJUVEK Toward European Approval for Dystrophic Epidermolysis Bullosa

Krystal Biotech Receives Positive CHMP Opinion For VYJUVEK® For The Treatment Of Dystrophic Epidermolysis Bullosa - Medical Device News Magazine

“The CHMP’s recommendation for approval of VYJUVEK is an exciting step towards our goal of delivering the first ever corrective therapy to DEB patients across Europe,” said Suma Krishnan, President of Research and Development at Krystal Biotech. “The CHMP’s support for a broad label, including treatment of patients from birth and the option of patient or caregiver administration at home, are also fantastic outcomes for the DEB patients we aim to…

Castle Creek gets $75M for DEB gene therapy Phase 3 trial

Castle Creek Biosciences has secured $75 million in financing to support a Phase 3 trial testing its gene therapy to promote wound healing in people with dystrophic epidermolysis bullosa (DEB). The royalty financing agreement for Castle Creek‘s treatment, D-Fi, was led by Ligand Pharmaceuticals, which made a $50 million investment. Ligand said the investors will get “a high single-digit royalty” on worldwide sales of the treatment if it is ultim…

# Krystal Biotech Advances VYJUVEK Toward European Approval for Dystrophic Epidermolysis Bullosa

In a significant development for genetic medicine, Krystal Biotech, Inc., a pioneering biotechnology firm based in Pittsburgh, has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) concerning its revolutionary product, VYJUVEK. This gene therapy, also known as beremagene geperpavec-svdt (B-VEC), is being evaluated for its potential to address the crippling genetic disorde…